Nov 4, 2013
Annals of Internal Medicine
Correction: Systemic Lupus Erythematosus
In a recent In the Clinic , in the last paragraph of the middle column on page 10, the second sentence should read, "Calcineurin inhibitors or rituximab combined with glucocorticoids may be used for patients with an inadequate response to cyclophosphamide or mycophenolate mofetil."
Medical News Today
Discontinuing mycophenolate acid products does not seem to pose risks ...
Research suggests that fetal exposure to mycophenolic acid products - which are drugs taken by transplant recipients to prevent rejection - may increase the risk of birth defects and spontaneous abortions.
Aurinia Shakes up Sr. Management, Cuts Staff
Isotechnika Pharma Inc., now operating as Aurinia Pharmaceuticals Inc. , announced today a strategic restructuring, including senior management changes and staff reductions, designed to further position the newly merged company to successfully bring voclosporin to market as a therapy for lupus nephritis.
Rx Product News
Astagraf XL Marketed by: Astellas Pharma US, Inc Indication: The FDA has approved Astagraf XL , a calcineurin-inhibitor immunosuppressant, for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction.
Kwang Dong Pharmaceutical Co., Ltd. (009290) - Pharmaceuticals &...
Kwang Dong Pharmaceutical Co., Ltd. is a healthcare company. It manufactures and sales oriental herbal medicines and pharmaceutical products.